


Thi-DPPY

Cat. No.:	HY-147742
CAS No.:	2307699-34-7
Molecular Formula:	C ₂₈ H ₂₈ ClN ₅ O ₄ S
Molecular Weight:	566.07
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC ₅₀ values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) ^[1] .									
IC₅₀ & Target	JAK3 1.38 nM (IC ₅₀)	BTK 62.4 nM (IC ₅₀)								
In Vitro	DPPY (compound 8e) shows anti-proliferative activity against HBE (human bronchial epithelia) cells with an IC ₅₀ of 39.0 μM [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
In Vivo	<p>DPPY (30, 60 mg/kg; i.g., once daily for 14 days) shows anti-IPF agents on the lung morphology and lung coefficient in mouse model^[1].</p> <p>DPPY (30, 60 mg/kg) significantly decreases the expression of IL-6, IL-17A, TNF-α and MDA in lung tissue in a dose dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>5-6 week old, 20-25 g, C57BL mice (BLM-induced pulmonary inflammation and pulmonary fibrosis model)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30, 60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.g.; once daily for 14 days</td> </tr> <tr> <td>Result:</td> <td>Attenuated the pulmonary morphology changes and reduced the collagen disposition induced by BLM in mouse lung.</td> </tr> </table>		Animal Model:	5-6 week old, 20-25 g, C57BL mice (BLM-induced pulmonary inflammation and pulmonary fibrosis model) ^[1]	Dosage:	30, 60 mg/kg	Administration:	i.g.; once daily for 14 days	Result:	Attenuated the pulmonary morphology changes and reduced the collagen disposition induced by BLM in mouse lung.
Animal Model:	5-6 week old, 20-25 g, C57BL mice (BLM-induced pulmonary inflammation and pulmonary fibrosis model) ^[1]									
Dosage:	30, 60 mg/kg									
Administration:	i.g.; once daily for 14 days									
Result:	Attenuated the pulmonary morphology changes and reduced the collagen disposition induced by BLM in mouse lung.									

REFERENCES

[1]. Zhu Y, et al. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. *Bioorg Med Chem.* 2020 Jan 15;28(2):115254.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA